Lung Cancer

Lung CancerA17:G22)
No. Study TitlePrinciple Investigator SponsorTypeRecruitingStudy status
1APPLE study: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive Plasma T790M in EGFR mutant NSCLC patients.Dr. Kamal Al-RabiEORTCClinical TrialNoOngoing
2CANOPY 2 study: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2).Dr. Sameer YaserNovartisClinical TrialNoOngoing
3CANOPY A study: A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cmN2) completely resected (R0) non-small cell.Dr. Sameer YaserNovartisClinical TrialYesOngoing
4EORTC 1825 ALKALINE study: Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor.Dr. Kamal Al-RabiEORTCClinical TrialPending Pending